Radical 064 Reperfusion Catheter; Radical 076 Reperfusion Catheter; Radical Aspiration Tubing Kit
Maduro Medical, Inc. · Decision date Sep 14, 2026
What did the FDA decide?
Maduro Medical, Inc. received a substantially equivalent (SESE) decision for K261089 on September 14, 2026, covering the Radical 064 Reperfusion Catheter, Radical 076 Reperfusion Catheter and Radical Aspiration Tubing Kit. The catheters are sterile, single-use intravascular devices for thrombus removal from the neurovasculature with a vacuum pump; the 064 and 076 designations reflect inner diameter sizes of 0.064" and 0.076", with usable lengths of 125–140 cm. The tubing kit is a 112" extension assembly with an on/off flow switch linking the catheter hub to a pump canister.
The submission lists the AXS Vecta Aspiration System (K191768) as predicate, with several reference devices including the Route 92 Medical HiPoint system (K243601). The summary states shared intended use and basic technological characteristics with the predicate. The public record does not include the clinical or bench evidence underlying the decision, and the two source pages give different received dates (August 11, 2026 in the letter, April 1, 2026 in the database entry). Indications described in the summary are those of the cleared labeling, not independently verified clinical findings.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 14, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K261089
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Maduro Medical, Inc.
- Product code
- NRY
- Decision code
- SESE
- Decision date
- Sep 14, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Catheter, Thrombus Retriever.
- Applicant
- Maduro Medical, Inc.
- Product code
- NRY
- FDA device class
- 2
FDA decision timeline
K261089 received
Application receipt date recorded by FDA.
K261089 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code NRY
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Toro Neurovascular, Inc. | 510(k) clearance | Oct 21, 2026 | FDA | |
| Route 92 Medical, Inc. | 510(k) clearance | Oct 16, 2026 | FDA | |
| Rapid-Medical , Ltd. | 510(k) clearance | Aug 28, 2026 | FDA | |
| Cerenovus, Inc. | 510(k) clearance | Aug 13, 2026 | FDA | |
| Alembic, LLC | 510(k) clearance | Aug 12, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Maduro Medical, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Los Gatos, CA
Sources and methodology
- Original FDA record: K261089
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

